Waters Corporation announced its $17.5 billion acquisition of Becton Dickinson’s Biosciences and Diagnostics Solutions business, marking the largest life sciences deal of 2025. The combined entity is positioned to broaden instrument portfolio to include flow cytometry, molecular diagnostics, and microbiology technologies, accelerating Waters’ clinical ambitions. The acquisition enhances competition with Bruker, complements Waters’ expertise in mass spectrometry and large molecule QA/QC, and aims to double total addressable market to approximately $40 billion.